mTOR signaling has previously been shown to be activated in human tRCC samples and pre-clinical models by transcriptomic and proteomic profiling18,24,25,27,28, including in a recent mouse model of ASPSCR1-TFE3 tRCC26, though this signaling pathway was not examined in the previously published PRCC-TFE3 transgenic mice4. The gene discussed is MTOR; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.